<DOC>
	<DOCNO>NCT02960815</DOCNO>
	<brief_summary>In open label , single centre , pilot randomize controlled clinical trial investigator aim compare immunogenicity safety new influenza vaccination strategy consist topical administration imiquimod injection site vaccination vs. standard intramuscular vaccine injection SOT recipients HIV-infected individual . The investigator plan enroll 70 outpatient patient ( 50 % solid-organ transplant recipient 50 % HIV-infected patient ) regularly follow Transplantation center Infectious disease outpatient ' clinic Lausanne University Hospital . Study participant randomize 1:1:1 ratio receive standard intramuscular vaccine ( control group ) topical application imiquimod contain cream follow intramuscular ( imiquimod-IM ) intradermal ( imiquimod-ID ) vaccine injection . After vaccination participant follow period 180 day . Blood sample draw baseline day 21 180 assessment immunogenicity . Safety outcome assess immediately vaccine administration , day 7 ( phone call ) , 21 180 .</brief_summary>
	<brief_title>Imiquimod Influenza Vaccine Immunocompromised Patients</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Provision write , inform consent Age &gt; 18 year HIV infection least 3 month kidney transplantation Stable outpatient Able willing comply study protocol Documented egg and/or imiquimod allergy Previous lifethreatening reaction seasonal influenza vaccine ( i.e . GuillainBarr√© Syndrome ) Previous severe reaction imiquimod cream Pregnancy breastfeeding Patients autoimmune disease For HIVinfected patient : Current active opportunistic infection For kidney transplant recipient : Ongoing therapy rejection ( include steroid pulse prednisone &gt; 2 mg/kg/day 14 day ) Ongoing therapy IVIG eculizumab current past ( &lt; 6months ) therapy rituximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>influenza vaccine</keyword>
	<keyword>Transplantation</keyword>
	<keyword>imiquimod</keyword>
	<keyword>HIV infection</keyword>
	<keyword>immunogenicity</keyword>
</DOC>